Takeda Pharmaceutical Company Limited (TAK)
NYSE: TAK · Real-Time Price · USD
18.14
+0.06 (0.30%)
Mar 4, 2026, 10:10 AM EST - Market open
Takeda Pharmaceutical Employees
Takeda Pharmaceutical Company had 47,455 employees as of March 31, 2025. The number of employees decreased by 1,826 or -3.71% compared to the previous year.
Employees
47,455
Change (1Y)
-1,826
Growth (1Y)
-3.71%
Revenue / Employee
$600,047
Profits / Employee
$15,177
Market Cap
56.13B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2025 | 47,455 | -1,826 | -3.71% |
| Mar 31, 2024 | 49,281 | 186 | 0.38% |
| Mar 31, 2023 | 49,095 | 1,748 | 3.69% |
| Mar 31, 2022 | 47,347 | 248 | 0.53% |
| Mar 31, 2021 | 47,099 | -396 | -0.83% |
| Mar 31, 2020 | 47,495 | -2,083 | -4.20% |
| Mar 31, 2019 | 49,578 | 22,348 | 82.07% |
| Mar 31, 2018 | 27,230 | -2,670 | -8.93% |
| Mar 31, 2017 | 29,900 | -1,268 | -4.07% |
| Mar 31, 2016 | 31,168 | -160 | -0.51% |
| Mar 31, 2015 | 31,328 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Teva Pharmaceutical Industries | 33,950 |
| Viatris | 30,000 |
| Dr. Reddy's Laboratories | 27,811 |
| Haleon | 24,561 |
| Zoetis | 14,500 |
| Elanco Animal Health | 9,900 |
| Alkermes | 2,050 |
| Neurocrine Biosciences | 2,000 |
TAK News
- 2 days ago - Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera - Business Wire
- 12 days ago - Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis - Business Wire
- 22 days ago - Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market - Benzinga
- 22 days ago - U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda's Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1 - Business Wire
- 22 days ago - Takeda Taps AI Startup Iambic In $1.7 Billion+ Deal To Speed Up Drug Discovery - Benzinga
- 22 days ago - Takeda Taps AI Startup Iambic In $1.7 Billion+ Deal To Speed Up Drug Discovery - Benzinga
- 23 days ago - Takeda deepens AI drug discovery push with $1.7 billion Iambic deal - Reuters
- 23 days ago - Iambic Announces Collaboration with Takeda to Advance AI-Driven Design of Small Molecules - Business Wire